11.png)
Department of General Medicine, Santosh Medical College and Hospital in collaboration with Delhi Diabetic forum organized and conducted a Diabetes, Hypertension, Metabolic Disease and NAFLD Screening Camp on 19 January 2024 to raise awareness about diabetes, metabolic diseases and its complication includes heart disease, atrial fibrillation, stroke, and thromboembolic diseases, and NAFLD in the Department of general Medicine, Santosh Hospital Ghaziabad.
The aim of the camp was to detect these diseases early and provide necessary medical attention to prevent complications. The camp was attended by around 75 people, and several medical professionals were present to conduct the tests.
The attendees were given a general health check-up, and their medical history was recorded. ECG was done and Blood samples were taken for ECG, spot glucose, HbA1C, lipid level testing and liver function testing, complete blood count and uric acid levels. Blood pressure and body mass index (BMI), waist circumference, were also measured. Liver stiffness measured by FIBROSCAN [transient electrography] devise that is noninvasive device used to measure liver scarring or fibrosis and Physician consultation.
Results: Out of the 75 attendees, 30 % had high blood pressure, and 28 % were overweight or obese with fibrosis score 2 i.e. moderate liver scarring. The majority of attendees were found to have high glucose and lipid levels, indicating a high risk of diabetes and dyslipidemia. Around 30 % of the attendees showed transaminitis with 12 % insulin resistance.
Recommendations: Those who were diagnosed with diabetes, NAFLD OR Metabolic disease and dyslipidemia, and were provided with medical consultation and treatment options. The attendees who were at high risk were advised to adopt a healthy lifestyle, including a balanced diet and regular physical activity, to prevent the onset of these diseases.
Conclusion: The last decade has been an exciting one for investigators and clinicians interested in understanding the broader consequences of NAFLD for chronic liver disease, HCC and for extra- hepatic diseases, such as type 2 diabetes, CVD and cardiac disease and CKD. More frequently do patients with NAFLD die from extra-hepatic complications of NAFLD (mainly from CVD causes) than liver disease per se and clearly with the epidemic of obesity and T2DM the prevalence of NAFLD is likely to markedly increase.
